THOR Therapeutics

Synthorx (often referred to as Thor Therapeutics due to its ticker symbol and program nomenclature) is a clinical-stage biotechnology company that was acquired by Sanofi in 2020 for $2.5 billion. The company is a pioneer in the field of synthetic biology, utilizing a proprietary platform that incorporates an expanded genetic alphabet with a third synthetic base pair (X and Y) to create novel "Synthorin" proteins. These proteins are engineered with precise modifications, such as site-specific pegylation, to optimize their pharmacology and therapeutic index. The company's lead program, SAR444245 (formerly THOR-707), is a non-alpha IL-2 variant designed to selectively stimulate effector T cells and natural killer cells for the treatment of various solid tumors. Synthorx's pipeline also includes engineered versions of IL-10, IL-15, and IL-21, targeting both oncology and autoimmune indications.